newsfilter
← Latest News
ClinicalTrials.gov·

A Phase I Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer - NCT05475847

Safety and tolerability of C-TIL052A cell therapy, Objective Response Rate (ORR), Disease Control Rate (DCR), (and 4 more...)